Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07254364 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Advancing Precision Nutrition: Wearable Technology for Noninvasive Insulin Monitoring

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Enrollment reduced 65% 92 → 32 participants
See other at-risk trials from Texas A&M University

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment reduced: 92 → 32 participants Show 5 more changesShow less
    • Lead sponsor: Texas A&M University to Texas A&M University
    • Interventions modified
    • Study description revised
    • Site details revised
    • Eligibility criteria shortened, about 3 words
  2. Notable Enrollment increased: 32 → 92 participants
    • Interventions modified
    • Eligibility criteria expanded, about 28 words
    • Study description revised
    v2
  3. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
5,087 trials monitored
See 222 trials at risk
886 trials monitored
See 40 trials at risk
Noninvasively monitoring insulin is crucial for advancing precision nutrition and promoting healthy living by enabling a deeper understanding of individual metabolic responses to dietary intake. Insulin is a key regulator of blood sugar and energy metabolism, and its dysregulation is linked to conditions such as diabetes, obesity, and metabolic syndrome. By noninvasively tracking insulin levels, individuals can gain real-time insights into how their body processes different foods, allowing for the personalization of diets to optimize metabolic health, manage weight, and reduce disease risk. This approach also empowers proactive lifestyle adjustments to maintain insulin sensitivity, improve glycemic control, and enhance overall well-being. Decentralized insulin quantification in biofluids, including saliva and serum, based on lateral flow assay or electrochemical sensor has been reported. However, these approaches have poor sensitivity and fail to quantify insulin with a high temporal resolution.
Trial Details
NCT Number NCT07254364
Lead Sponsor Texas A&M University
Conditions
(from sponsor)
Insulin Response, Type 1 Diabetes
Related terms Diabetes Mellitus, Type 1
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov